(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
The cave was pitch black – so to create this magical underwater shot, the photographer had to use all his camera expertise...- Lilly, Novo lock horns in India's obesity drug race
- FDA proposes use of sunscreen ingredient popular in other countries
- Home Mechanization Frameworks for Brilliant Residing
- Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- Manual for Purchasing a Modest Jeep Wrangler for Seniors
- See the first close-up photos of the moon from NASA's Artemis II mission
- I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.
- The most effective method to Pick the Right Volvo XC40 Trim for Your Way of life
